---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-007044"
form_type: "8-K"
ticker: "SNOA"
cik: "0001367083"
company_name: "Sonoma Pharmaceuticals, Inc."
filed_at: "2023-10-11T23:59:59+00:00"
generated_at: "2026-06-10T01:33:39.930217+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Sonoma Pharmaceuticals provides updated investor presentation; no material changes disclosed

## Summary
- Exhibit 99.1 contains an updated corporate presentation dated October 2023.
- Presentation reiterates focus on stabilized hypochlorous acid products across multiple therapeutic areas.
- Company states products sold directly or via partners in 55 countries.
- No new financial guidance, product approvals, or strategic transactions disclosed in the filing.

## SEC filing metadata
- accession: 0001683168-23-007044
- form_type: 8-K
- ticker: SNOA
- cik: 0001367083
- company_name: Sonoma Pharmaceuticals, Inc.
- filed_at: 2023-10-11T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367083/000168316823007044/0001683168-23-007044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367083/000168316823007044/sonoma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-007044
- JSON: https://secwatch.observer/filing/0001683168-23-007044.json
- Plain text: https://secwatch.observer/filing/0001683168-23-007044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.